CVRx touts positive two-year data for heart failure neuromodulation device
Building on long-term data announced earlier this year, CVRx has reported durable improvements in heart failure patients with its Barostim…
Cardiovascular
-
-
CorFlow secures $48.5m for microvascular obstruction detection device
CorFlow Therapeutics has raised $48.5m (€44m) in a Series B financing round to advance its microvascular obstruction (MVO) detection device…
-
Arrowhead to file NDA after pivotal rare disease trial meets all endpoints
Arrowhead Pharmaceuticals is looking to file a new drug application (NDA) with the US Food and Drug Administration (FDA) after…
-
ESC 2024: Elixir’s stent contender hits primary endpoint in CAD trial
Elixir Medical’s DynamX Bioadaptor scaffold for coronary artery disease (CAD) has produced positive results in a randomised controlled trial comparing…
-
Study identifies blood biomarkers for predicting 30-year heart risks
A study sponsored by the US National Institutes of Health (NIH) has found that measuring three blood biomarkers can be…
-
Bristol Myers Squibb’s CAMZYOS offers benefits in oHCM trial
Bristol Myers Squibb (BMS) has unveiled new long-term follow-up results from the EXPLORER-LTE cohort of the MAVA-long-term extension (LTE) clinical…
-
ESC 2024: FINEARTS-HF trial sheds positive light on Kerendia for HFmrEF/HFpEF
On 1 September, at this year’s European Society of Cardiology (ESC) conference, during a late-breaking “Hot Line” session the highly…
-
ESC 2024: Sacubitril/valsartan continues to impress in heart failure
On 31 August, at this year’s European Society of Cardiology (ESC) conference, during a late-breaking science session on the topic…
-
ESC 2024: Retatrutide improves lipid and cardiovascular risk profile in Phase II trial
This morning at the European Society of Cardiology (ESC) Congress 2024, Eli Lilly and Co announced the most recent trial…
-
CellProthera inches closer to Phase III trial for heart attack cell therapy
CellProthera has reported a positive pre-investigational new drug (IND) meeting with the US Food and Drug Administration (FDA), as a…
